JP2008521907A - 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー - Google Patents

抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー Download PDF

Info

Publication number
JP2008521907A
JP2008521907A JP2007544441A JP2007544441A JP2008521907A JP 2008521907 A JP2008521907 A JP 2008521907A JP 2007544441 A JP2007544441 A JP 2007544441A JP 2007544441 A JP2007544441 A JP 2007544441A JP 2008521907 A JP2008521907 A JP 2008521907A
Authority
JP
Japan
Prior art keywords
igf1r
seq
pta
cancer
phosphorylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007544441A
Other languages
English (en)
Japanese (ja)
Inventor
ヤン ワン，
ジョナサン パクター，
ヤオリン ワン，
ミン リュー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2008521907A publication Critical patent/JP2008521907A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2007544441A 2004-12-03 2005-11-30 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー Withdrawn JP2008521907A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63315604P 2004-12-03 2004-12-03
PCT/US2005/043184 WO2006060419A2 (en) 2004-12-03 2005-11-30 Biomarkers for pre-selection of patients for anti-igf1r therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011108837A Division JP2011157397A (ja) 2004-12-03 2011-05-13 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー

Publications (1)

Publication Number Publication Date
JP2008521907A true JP2008521907A (ja) 2008-06-26

Family

ID=36190453

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007544441A Withdrawn JP2008521907A (ja) 2004-12-03 2005-11-30 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー
JP2011108837A Pending JP2011157397A (ja) 2004-12-03 2011-05-13 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー
JP2011280276A Pending JP2012067124A (ja) 2004-12-03 2011-12-21 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011108837A Pending JP2011157397A (ja) 2004-12-03 2011-05-13 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー
JP2011280276A Pending JP2012067124A (ja) 2004-12-03 2011-12-21 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー

Country Status (11)

Country Link
US (1) US7811562B2 (https=)
EP (3) EP2283831A3 (https=)
JP (3) JP2008521907A (https=)
AT (1) ATE493442T1 (https=)
CA (1) CA2589885A1 (https=)
DE (1) DE602005025685D1 (https=)
ES (1) ES2356830T3 (https=)
MX (1) MX2007006640A (https=)
PT (1) PT1828249E (https=)
TW (1) TWI376233B (https=)
WO (1) WO2006060419A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515271A (ja) * 2009-12-22 2013-05-02 エクスプレッション、パソロジー、インコーポレイテッド インスリン受容体基質１（ｉｒｓ１）タンパク質ｓｒｍ／ｍｒｍアッセイ

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080193445A1 (en) * 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
US7217796B2 (en) * 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
AU2003256299A1 (en) 2002-07-01 2004-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
WO2005016970A2 (en) 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
US20100035244A1 (en) 2005-04-14 2010-02-11 The Trustees Of Boston University Diagnostic for lung disorders using class prediction
WO2006113483A2 (en) * 2005-04-15 2006-10-26 Schering Corporation Methods and compositions for treating or preventing cancer
CA2612449A1 (en) 2005-06-17 2006-12-28 Imclone Systems Incorporated Receptor antagonists for treatment of metastatic bone cancer
AU2006292278B2 (en) 2005-09-20 2012-03-08 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
JP5198289B2 (ja) 2006-02-03 2013-05-15 イムクローン・リミテッド・ライアビリティ・カンパニー 前立腺癌の治療用アジュバントとしてのｉｇｆ−ｉｒアンタゴニスト
WO2007093008A1 (en) * 2006-02-17 2007-08-23 Adelaide Research & Innovation Pty Ltd Antibodies to insulin-like growth factor i receptor
WO2007103541A2 (en) 2006-03-09 2007-09-13 The Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US20080112888A1 (en) * 2006-06-30 2008-05-15 Schering Corporation Igfbp2 biomarker
WO2008054597A2 (en) * 2006-09-28 2008-05-08 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
CA2672828A1 (en) * 2006-12-13 2008-06-26 Schering Corporation Methods of treatment
EP2145021A2 (en) * 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
WO2009017679A2 (en) * 2007-07-31 2009-02-05 Merck & Co., Inc. Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
JP2010538680A (ja) * 2007-09-19 2010-12-16 ザ トラスティーズ オブ ボストン ユニバーシティー 肺疾患に対する薬剤開発のための新規経路の同定
JP2011501660A (ja) * 2007-10-03 2011-01-13 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド インスリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌反応を予測する生物学的マーカー
JP2010540960A (ja) * 2007-10-03 2010-12-24 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド インスリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌反応を予測する生物学的マーカー
MX2010006854A (es) 2007-12-18 2010-09-09 Schering Corp Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.
AU2009314111A1 (en) * 2008-11-12 2010-05-20 Merck Sharp & Dohme Corp. BetaGI-IgG intron for enhanced anti-IGF1 R expression
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US20110171124A1 (en) * 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
US8669057B2 (en) 2009-05-07 2014-03-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
US8765713B2 (en) 2009-10-30 2014-07-01 Keio University Method for determination of sensitivity to anti-cancer agent
EP2494070A2 (en) * 2009-10-30 2012-09-05 Bristol-Myers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
CA2783656A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2783665A1 (en) * 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
MX349662B (es) * 2010-07-22 2017-08-08 Univ California Anticuerpos de antigenos antitumorales y metodos de uso.
TW201302793A (zh) * 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CA2825894C (en) 2011-02-02 2021-11-30 Amgen Inc. Prognosis of cancer using a circulating biomarker
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013056069A1 (en) * 2011-10-13 2013-04-18 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
EP3215170A4 (en) 2014-11-05 2018-04-25 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
ES2884844T3 (es) 2015-03-09 2021-12-13 Agensys Inc Conjugados de anticuerpo fármaco (ADC) que se unen a proteínas FLT3
EP4180531A3 (en) 2016-05-12 2023-08-23 Trustees of Boston University Nasal epithelium gene expression signature and classifier for the prediction of lung cancer
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
KR20220164773A (ko) * 2020-04-08 2022-12-13 앨리어다 테라퓨틱스, 인코포레이티드 혈액-뇌 장벽 전달용 조성물 및 방법
CN119792512A (zh) 2020-10-14 2025-04-11 维里迪安治疗公司 用于治疗甲状腺眼病的组合物和方法
TW202320850A (zh) * 2021-08-10 2023-06-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物、劑量及方法
IL326876A (en) * 2023-09-06 2026-04-01 Viridian Therapeutics Inc Pharmaceutical preparations of anti-IGF-1R antibodies

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053596A2 (en) * 2001-01-05 2002-07-11 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
WO2002092599A1 (en) * 2001-05-14 2002-11-21 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine derivatives
WO2003039538A1 (en) * 2001-11-07 2003-05-15 Biotech Research Ventures Pte Ltd Composition containing a flavonoid glycone and method for using same as anti-proliferative
WO2003059951A2 (fr) * 2002-01-18 2003-07-24 Pierre Fabre Medicament Anticorps anti-igf-ir et leurs applications
WO2003100008A2 (en) * 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
WO2003100059A2 (en) * 2002-05-28 2003-12-04 Isis Innovation Ltd. Molecular targeting of the igf-1 receptor
WO2003106621A2 (en) * 2002-06-14 2003-12-24 Immunogen, Inc. Anti-igf-i receptor antibody
WO2004030625A2 (en) * 2002-10-02 2004-04-15 Bristol-Myers Squibb Company Synergistic methods and compositions for treating cancer
WO2004071529A2 (en) * 2003-02-13 2004-08-26 Pfizer Products Inc. Uses of anti-insulin-like growth factor i receptor antibodies
WO2004083248A1 (en) * 2003-03-14 2004-09-30 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
WO2004087756A2 (en) * 2003-04-02 2004-10-14 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2005016970A2 (en) * 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4543439A (en) * 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
CA2058041A1 (en) 1990-06-27 1991-12-28 Katsuichi Sakano Anti-igf-ii monoclonal antibody
US6300129B1 (en) * 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5198340A (en) * 1991-01-17 1993-03-30 Genentech, Inc. Assay for free igf-i, igf-ii, and gh levels in body fluids
US5262308A (en) * 1992-01-28 1993-11-16 Thomas Jefferson University Cell lines which constitutively express IGF-1 and IGF-1 R
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
ATE191853T1 (de) * 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
JPH08508409A (ja) * 1993-04-06 1996-09-10 シーダーズ − サイナイ メディカル センター 変異インスリン様増殖因子▲ｉ▼受容体サブユニットおよびそれらの使用方法
US20020022023A1 (en) * 1999-01-15 2002-02-21 Axel Ullrich Treatment of diabetes mellitus and insulin receptor signal transduction
AUPM672594A0 (en) 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
EP0861267A4 (en) * 1995-11-14 2000-02-02 Univ Jefferson INDUCTION AND RESISTANCE TO TUMOR GROWTH BY MEANS OF SOLUBLE IGF-1
US6346390B1 (en) * 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
US5958872A (en) * 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use
AUPN999096A0 (en) 1996-05-22 1996-06-13 Northstar Biologicals Pty Ltd Peptides, antibodies, vaccines & uses thereof
US20020107187A1 (en) * 1996-05-22 2002-08-08 Kingston David J. Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof
US20020155095A1 (en) * 1996-10-18 2002-10-24 Tattanahalli L. Nagabhushan Methods and compositions for delivery and expression of interferon-a nucleic acids
ES2136583T1 (es) 1996-10-18 1999-12-01 Canji Inc Procedimientos y composiciones para el suministro y expresion de acidos nucleicos de interferon alfa.
WO1998022092A1 (en) 1996-11-22 1998-05-28 The Regents Of The University Of California Transport of liposomes across the blood-brain barrier
US6294330B1 (en) * 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
DE19719001C2 (de) 1997-05-06 2001-05-10 Schuetzdeller Angelika Verfahren zum immunologisch-funktionalen Nachweis biologisch aktiver Insulin-Like Growth Factor Binding Proteine oder löslicher Insulin-Like Growth Factor - Rezeptoren im Immunoassay
BR9815289A (pt) 1997-11-14 2001-12-26 Euro Celtique Sa Imunoglobulina modificada, molécula, ácidonucleico isolado, célula contendo o mesmo, animalnão-humano recombinante, composiçãofarmacêutica, composição de vacina, processospara identificar ou medir ou detectar um antìgenode câncer, um antìgeno de um agente de doençainfecciosa, um ligante, e um receptor em umaamostra a ser testada, kits para detecção de umantìgeno de câncer, de um antìgeno de um agentede doença infecciosa, de um receptor celular paraum agente de doença infecciosa, de um ligante, e deum antìgeno de câncer, processos de diagnósticoou de exame para a presença de ou umapredisposição para desenvolvimento de um câncertipificado pela presença aumentada de umantìgeno de câncer, e para a presença de umagente de doença infecciosa, processos detratamento ou de prevenção de um câncertipificado pela presença de um antìgeno de câncer,de uma doença infecciosa tipificada pela presençade um antìgeno de agente de doença infecciosa, ede uma doença causada por um agente de doençainfecciosa que se liga em um receptor celular,processos para modulação de atividade de umprimeiro membro de um par de ligação, processo deprodução de uma imunoglobulina modificada,processo de produção de um ácido nucleicocodificador de imunoglobulina modificada, e, ácidonucleico isolado
DE69834828T2 (de) 1997-11-27 2007-01-04 Commonwealth Scientific And Industrial Research Organisation Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462)
JP2002508160A (ja) 1998-02-24 2002-03-19 レセプトロン，インコーポレイティド 受容体活性のモジュレーターとしての受容体由来ペプチド
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
KR20010071271A (ko) 1998-05-15 2001-07-28 존 비. 랜디스 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US20030236190A1 (en) * 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
US7173005B2 (en) * 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
JP2002527066A (ja) 1998-10-15 2002-08-27 カイロン コーポレイション 転移性乳癌および結腸癌調節遺伝子
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
AU3579200A (en) 1999-02-26 2000-09-14 Saltech I Goteborg Ab Method and composition for the regulation of hepatic and extrahepatic productionof insulin-like growth factor-1
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
WO2000069454A1 (en) 1999-05-17 2000-11-23 Board Of Regents, The University Of Texas System Suppression of endogenous igfbp-2 to inhibit cancer
AU6607100A (en) 1999-07-23 2001-02-13 Regents Of The University Of California, The Anti-growth factor receptor avidin fusion proteins as universal vectors for drugdelivery
WO2001030964A2 (en) 1999-10-22 2001-05-03 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AU1410801A (en) 1999-11-17 2001-05-30 Compugen Ltd. Variants of alternative splicing
AU2135001A (en) * 1999-12-15 2001-06-25 Mcgill University Targeting of endosomal growth factor processing as anti-cancer therapy
AU2001245888A1 (en) 2000-03-21 2001-10-03 University Of South Florida Growth factor binding molecules
EP1265635A1 (en) 2000-03-22 2002-12-18 Glaxo Group Limited Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
WO2001072771A2 (en) 2000-03-29 2001-10-04 Dgi Biotechnologies, L.L.C. Insulin and igf-1 receptor agonists and antagonists
EP1268510A4 (en) 2000-03-31 2003-05-28 Hyseq Inc METHOD AND MATERIALS REGARDING INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN POLYPEPTIDES AND POLYNUCLEOTIDES
US6372250B1 (en) * 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
US7329745B2 (en) * 2000-06-13 2008-02-12 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
CA2414272A1 (en) 2000-07-10 2002-01-17 Novartis Ag Bifunctional molecules and vectors complexed therewith for targeted gene delivery
US20020164333A1 (en) * 2000-07-10 2002-11-07 The Scripps Research Institute Bifunctional molecules and vectors complexed therewith for targeted gene delivery
WO2002007783A2 (en) 2000-07-20 2002-01-31 Regents Of The University Of Minnesota Radiolabeled immunotoxins
US20030162230A1 (en) 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
US8153121B2 (en) * 2000-10-06 2012-04-10 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
DE10050338A1 (de) 2000-10-11 2002-04-25 Deutsches Krebsforsch Auf dem Nachweis von IGF-IRbeta und IRS-1 beruhendes Diagnose- bzw. Klassifizierungsverfahren für Carcinome
AU2002213196A1 (en) * 2000-10-12 2002-04-22 Icos Corporation Modulation of ligand binding/enzymatic activity of alpha beta proteins
JP2004529315A (ja) * 2000-11-03 2004-09-24 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム 抗癌処置の効力を検出するための方法
JP2004517078A (ja) 2000-12-01 2004-06-10 シェーリング　コーポレイション 哺乳動物遺伝子および関連試薬の使用
DE60140074D1 (de) 2000-12-14 2009-11-12 Burnham Inst Non-apoptotische formen des zelltods und verfahren zur modulation
DK1395669T3 (da) * 2001-01-26 2009-11-16 Selexis Sa Matriks bindingsregioner og fremgangsmåder til anvendelse af disse
US7071300B2 (en) * 2001-03-14 2006-07-04 Genentech, Inc. IGF antagonist peptides
US20040116330A1 (en) * 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
FR2824076B1 (fr) 2001-04-27 2003-06-13 Centre Nat Rech Scient Methode de detection de composes activateurs ou inhibiteurs des recepteurs de la famille du recepteur de l'insuline au moyen d'un recepteur chimere isole
US7498029B2 (en) * 2001-05-01 2009-03-03 The General Hospital Corporation Photoimmunotherapies for cancer using combination therapies
AU2002329540A1 (en) 2001-06-20 2003-01-02 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20050037445A1 (en) 2001-06-25 2005-02-17 Poulsen Hans Skovgaard Oncology drug innovation
IL160091A0 (en) 2001-08-06 2004-06-20 Stil Biotechnologies Ltd Methods of identifying functional analogs of peptide regulators of biological pathways
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US7553485B2 (en) 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
FR2834900B1 (fr) 2002-01-18 2005-07-01 Pf Medicament Nouvelles compositions a activite anti-igf-ir et anti-egfr et leurs applications
FR2834991B1 (fr) 2002-01-18 2004-12-31 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
FR2834990A1 (fr) 2002-01-18 2003-07-25 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
WO2003088910A2 (en) 2002-04-15 2003-10-30 Rigel Pharmaceuticals, Inc. Methods of assaying for cell cycle modulators
US7655397B2 (en) * 2002-04-25 2010-02-02 The United States Of America As Represented By The Department Of Health And Human Services Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers
JP4335130B2 (ja) 2002-04-30 2009-09-30 協和発酵キリン株式会社 ヒトインスリン様成長因子に対する抗体
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
WO2004007673A2 (en) * 2002-07-12 2004-01-22 The Johns Hopkins University Neuronal gene expression patterns
US20040142381A1 (en) * 2002-07-31 2004-07-22 Hubbard Stevan R. Methods for designing IGF1 receptor modulators for therapeutics
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
US20030138430A1 (en) * 2002-09-20 2003-07-24 Stimmel Julie Beth Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
JP2007524566A (ja) 2002-12-20 2007-08-30 エンカム ファーマシューティカルズ アクティーゼルスカブ レセプターとリガンドの間の相互作用の調節の方法
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
MXPA06001634A (es) 2003-08-13 2006-04-28 Pfizer Prod Inc Anticuerpos humanos modificados igf-1r.
DE10348391B3 (de) * 2003-10-17 2004-12-23 Beru Ag Verfahren zum Glühen einer Glühkerze für einen Dieselmotor
JP2007510434A (ja) * 2003-11-12 2007-04-26 シェーリング　コーポレイション 多重遺伝子発現のためのプラスミドシステム
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
US20050272637A1 (en) * 2004-04-22 2005-12-08 Oregon Health & Science University Compositions and methods for modulating signaling mediated by IGF-1 receptor and erbB receptors
MXPA06014021A (es) 2004-06-04 2007-02-08 Pfizer Prod Inc Procedimiento para tratar crecimiento celular anormal.
KR20070036130A (ko) * 2004-07-16 2007-04-02 화이자 프로덕츠 인코포레이티드 항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료
JP2008512352A (ja) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
WO2006113483A2 (en) * 2005-04-15 2006-10-26 Schering Corporation Methods and compositions for treating or preventing cancer
EA200702239A1 (ru) * 2005-04-15 2008-10-30 Иммьюноджен, Инк. Уничтожение гетерогенной или смешанной клеточной популяции в опухолях
KR20080019249A (ko) * 2005-06-15 2008-03-03 쉐링 코포레이션 안정한 항체 제형
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007093008A1 (en) 2006-02-17 2007-08-23 Adelaide Research & Innovation Pty Ltd Antibodies to insulin-like growth factor i receptor
US20080112888A1 (en) * 2006-06-30 2008-05-15 Schering Corporation Igfbp2 biomarker

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053596A2 (en) * 2001-01-05 2002-07-11 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
WO2002092599A1 (en) * 2001-05-14 2002-11-21 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine derivatives
WO2003039538A1 (en) * 2001-11-07 2003-05-15 Biotech Research Ventures Pte Ltd Composition containing a flavonoid glycone and method for using same as anti-proliferative
WO2003059951A2 (fr) * 2002-01-18 2003-07-24 Pierre Fabre Medicament Anticorps anti-igf-ir et leurs applications
WO2003100008A2 (en) * 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
WO2003100059A2 (en) * 2002-05-28 2003-12-04 Isis Innovation Ltd. Molecular targeting of the igf-1 receptor
WO2003106621A2 (en) * 2002-06-14 2003-12-24 Immunogen, Inc. Anti-igf-i receptor antibody
WO2004030625A2 (en) * 2002-10-02 2004-04-15 Bristol-Myers Squibb Company Synergistic methods and compositions for treating cancer
WO2004071529A2 (en) * 2003-02-13 2004-08-26 Pfizer Products Inc. Uses of anti-insulin-like growth factor i receptor antibodies
WO2004083248A1 (en) * 2003-03-14 2004-09-30 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
WO2004087756A2 (en) * 2003-04-02 2004-10-14 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2005016970A2 (en) * 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515271A (ja) * 2009-12-22 2013-05-02 エクスプレッション、パソロジー、インコーポレイテッド インスリン受容体基質１（ｉｒｓ１）タンパク質ｓｒｍ／ｍｒｍアッセイ
US9417246B2 (en) 2009-12-22 2016-08-16 Expression Pathology, Inc. Insulin receptor substrate 1 (IRS1) protein SRM/MRM assay
US10054592B2 (en) 2009-12-22 2018-08-21 Expression Pathology, Inc. Insulin receptor substrate 1 (IRS1) protein SRM/MRM assay

Also Published As

Publication number Publication date
EP1828249A2 (en) 2007-09-05
WO2006060419A9 (en) 2006-07-20
US7811562B2 (en) 2010-10-12
EP2281841A3 (en) 2013-10-23
WO2006060419A2 (en) 2006-06-08
PT1828249E (pt) 2011-02-25
MX2007006640A (es) 2007-06-19
EP2283831A2 (en) 2011-02-16
TWI376233B (en) 2012-11-11
EP1828249B1 (en) 2010-12-29
DE602005025685D1 (de) 2011-02-10
ES2356830T3 (es) 2011-04-13
JP2012067124A (ja) 2012-04-05
WO2006060419A3 (en) 2006-08-24
CA2589885A1 (en) 2006-06-08
EP2281841A2 (en) 2011-02-09
US20060140960A1 (en) 2006-06-29
JP2011157397A (ja) 2011-08-18
ATE493442T1 (de) 2011-01-15
EP2283831A3 (en) 2013-10-23
TW200626174A (en) 2006-08-01

Similar Documents

Publication Publication Date Title
EP1828249B1 (en) Biomarkers for pre-selection of patients for anti-igf1r therapy
JP7116113B2 (ja) がんを治療するためのｐｄ－１／ｐｄ－ｌ１阻害剤
RU2765997C2 (ru) Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования
JP7482180B2 (ja) 癌のための併用療法
US20080112888A1 (en) Igfbp2 biomarker
JP2011236253A (ja) 抗ｉｇｆｒ１抗体治療用組み合わせ
JP6941565B2 (ja) がん転移を処置または防止するのに有用な化合物および組成物、ならびにこれらの使用法
EP4559477A2 (en) Compositions and methods for treating cancer
KR20150041783A (ko) Ｉｇｆ1 ｒ 및 ｐｉ3ｋ에 대한 억제제의 병용 요법
EP3957326A1 (en) Use of anti-pd-1 antibody in preparation of medicament for treating solid tumors
US20120058112A1 (en) Antibodies
WO2021155840A1 (zh) 抗pd-1抗体在治疗恶性肿瘤中的用途
WO2021227326A1 (en) Compositions and methods for treating cancer
US8323883B1 (en) Methods of assessing therapeutic benefits of patients having cancers resistant to epidermal growth factor receptor kinase inhibitors
US20230365691A1 (en) Use of anti-pd-1 antibody in treatment of nasopharyngeal carcinoma
HK40066498A (en) Use of anti-pd-1 antibody in preparation of medicament for treating solid tumors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110415

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110513

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110824

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20111221